OUP user menu

★ Novel therapeutic concepts ★

Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice

Faiez Zannad, Wendy Gattis Stough, Patrick Rossignol, Johann Bauersachs, John J.V. McMurray, Karl Swedberg, Allan D. Struthers, Adriaan A. Voors, Luis M. Ruilope, George L. Bakris, Christopher M. O'Connor, Mihai Gheorghiade, Robert J. Mentz, Alain Cohen-Solal, Aldo P. Maggioni, Farzin Beygui, Gerasimos S. Filippatos, Ziad A. Massy, Atul Pathak, Ileana L. Piña, Hani N. Sabbah, Domenic A. Sica, Luigi Tavazzi, Bertram Pitt
DOI: http://dx.doi.org/10.1093/eurheartj/ehs257 2782-2795 First published online: 31 August 2012

Abstract

Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure, reduced ejection fraction (HF–REF), and mild-to-severe symptoms, and in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction. These clinical benefits are observed in addition to those of angiotensin converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers. The morbidity and mortality benefits of MRAs may be mediated by several proposed actions, including antifibrotic mechanisms that slow heart failure progression, prevent or reverse cardiac remodelling, or reduce arrhythmogenesis. Both eplerenone and spironolactone have demonstrated survival benefits in individual clinical trials. Pharmacologic differences exist between the drugs, which may be relevant for therapeutic decision making in individual patients. Although serious hyperkalaemia events were reported in the major MRA clinical trials, these risks can be mitigated through appropriate patient selection, dose selection, patient education, monitoring, and follow-up. When used appropriately, MRAs significantly improve outcomes across the spectrum of patients with HF–REF.

  • Heart failure
  • Aldosterone antagonist spironolactone
  • Mineralocorticoid receptors

Introduction

Mineralocorticoid receptor antagonists (MRAs), often referred to as aldosterone antagonists, are a key component of evidence-based therapy for patients with heart failure and reduced left ventricular ejection fraction (HF–REF or ‘systolic heart failure’). These agents have demonstrated morbidity and mortality benefits across the spectrum of HF–REF, including patients with mild1 to severe2 heart failure symptoms, as well as in patients with signs and symptoms of heart failure after acute myocardial infarction (AMI).3

This paper provides both state-of-the-art and practical information regarding the optimal use of MRAs in patients with heart failure. This topic was discussed among a panel of heart failure experts, cardiovascular clinical trialists, biostatisticians, National Institutes of Health (NIH) scientists, US and European government regulators, and pharmaceutical industry researchers during the Eighth Global Cardiovascular Clinical Trialists Forum held in Paris, France in December 2011. This review summarizes the current body of knowledge pertaining to MRAs in heart failure, targets for future research, and strategies practicing clinicians can employ to optimize MRA use in appropriate patients, thereby ultimately improving clinically relevant outcomes.

Review of the evidence and current indications

Primary evidence from randomized controlled trials

Severe heart failure

Recognition of aldosterone as an important neurohormonal modulator of heart failure progression dates back more than six decades.46 These early data led to the conceptual framework that combining an angiotensin converting enzyme (ACE) inhibitor and spironolactone may achieve more complete inhibition of the renin–angiotensin–aldosterone system (RAAS) and may produce further clinical benefits. The findings of a pilot study6,7 led to the design and conduct of the Randomized Aldactone Evaluation Study (RALES), which was the first large, prospective, randomized mortality trial of an MRA in patients with heart failure.2 The RALES data have been widely discussed in the literature. Briefly, 1663 patients with LVEF ≤35% and NYHA class IV heart failure symptoms within 6 months before enrolment and NYHA class III or IV symptoms at the time of enrolment were randomized to spironolactone 25 mg per day or placebo. After 8 weeks of treatment, the dose could be increased to 50 mg once daily if the patient showed signs or symptoms of heart failure progression without evidence of hyperkalaemia. It is important to note that strict eligibility criteria and laboratory monitoring were used in RALES and all of the subsequent MRA heart failure trials (Table 1). The primary endpoint was all-cause mortality. After a mean follow-up of 24 months, the study was stopped after the data monitoring committee advised the Steering Committee that the pre-specified efficacy boundary for mortality had been crossed. Patients randomized to spironolactone had a lower risk of death from any cause when compared with placebo (RR 0.70, 95% CI 0.60–0.82, P < 0.001) (Figure 1).2 Spironolactone also significantly reduced cause-specific mortality. Sudden death was reduced by 29% (RR 0.71, 95% CI 0.54–0.95, P = 0.02), and death due to progressive heart failure was reduced by 36% (RR 0.64, 95% CI 0.51–0.8, P < 0.001). Beta-blocker use was low (11%). As anticipated in a population receiving background ACE-inhibition, patients randomized to spironolactone had an increase in median potassium concentration of 0.3 mmol/L, but the incidence of serious hyperkalaemia (serum potassium ≥ 6 mmol/L) was not significantly different between the spironolactone and placebo groups [14 spironolactone patients (2%) vs. 10 placebo patients (1%), P = 0.42]. Treatment discontinuation due to any adverse event occurred in 8% of patients randomly assigned to spironolactone and in 5% of the placebo group.

View this table:
Table 1

Key exclusion criteria and monitoring procedures in major mineralocorticoid receptor antagonist heart failure trials

TrialMajor exclusionsMonitoring scheduleDose adjustment
Renal exclusionsPotassium exclusionsOther relevant exclusions
RALES2SCr > 2.5 mg/dL (221 µmol/L)>5 mmol/L
  • Potassium-sparing diuretics

  • Oral potassium supplements (unless hypokalaemia, K < 3.5 mmol/L)

At weeks 1 and 5, and every 4 weeks for first 12 weeks, then every 3 months for 1 year, then every 6 months thereafterDecrease dose to 25 mg every other day for hyperkalaemia, but dose adjustment of other medications encouraged first
EPHESUS3SCr > 2.5 mg/dL (221 µmol/L)>5 mmol/LPotassium-sparing diureticsAt 48 h after initiation; at 1, 4, and 5 weeks; then every 3 months thereafter; and within 1 week after any dose changeDose reduced or temporarily discontinued for serum potassium >5.5 mmol/L, until it fell below this value
EMPHASIS-HF1eGFR < 30 mL/min/1.73 m2>5 mmol/LPotassium-sparing diuretics
  • At 4 weeks, then every 4 months thereafter

  • Within 72 h of a dose adjustment due to hyperkalaemia

  • Decrease dose for potassium 5.5–5.9 mmol/L

  • Withhold drug for serum potassium >6 mmol/L, and restart when potassium < 5 mmol/L

Figure 1

RALES Kaplan–Meier survival analysis. From New England Journal of Medicine, Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure, Volume 341, page 712. Copyright © (1999) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Left ventricular systolic dysfunction and heart failure after acute myocardial infarction

The recognition of aldosterone as a mediator of ventricular remodelling and fibrosis led to its investigation in patients with LV dysfunction and heart failure after acute MI in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).3 Patients were randomized to eplerenone 25 mg per day or placebo for 4 weeks, after which the dose of eplerenone was increased to a maximum of 50 mg per day. The major exclusion criteria and monitoring procedures are shown in Table 1. Eplerenone reduced time to death from any cause (RR 0.85, 95% CI 0.76–0.96, P = 0.008) and the composite of time to cardiovascular death or first cardiovascular hospitalization (defined as admission with heart failure, AMI, stroke, or ventricular arrhythmia) (RR 0.87, 95% CI 0.79–0.95, P = 0.002) when compared with placebo (Figure 2).3 The majority of patients (86%) received concomitant background ACE-inhibitor or angiotensin receptor blocker (ARB) therapy. Serious hyperkalaemia (≥6 mmol/L) was reported more often in the eplerenone group (5.5 vs. 3.9%, P = 0.002); conversely, patients randomized to eplerenone had a lower incidence of serious hypokalaemia (<3.5 mmol/L) when compared with placebo (8.4 vs. 13.1%, P < 0.001).3 One hundred forty-seven patients (4.4%) in the eplerenone group and 149 (4.5%) in the placebo group withdrew due to adverse events.

Figure 2

Kaplan–Meier estimates of all-cause death (A) and cardiovascular death or cardiovascular hospitalization (B) in EPHESUS. From New England Journal of Medicine, Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction, volume 348, page 1314, copyright (c) 2003 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Heart failure with reduced ejection fraction and mild symptoms

Most recently, the clinical efficacy of an MRA has been confirmed in patients with HF–REF and mild symptoms in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) trial (Figure 3).1 Patients >55 years of age were enrolled with NYHA class II symptoms and LVEF ≤ 35% (QRS duration >130 ms was also required if LVEF was >30–35%) within 6 months of a cardiovascular hospitalization. Additional BNP eligibility criteria were required for patients who had not been hospitalized within the previous 6 months [BNP level ≥250 pg/mL, or NT pro-BNP ≥ 500 pg/mL (men) or 750 pg/mL (women)]. Patients with a recent acute MI or those with NYHA class III or IV symptoms were excluded, as were patients with serum potassium >5.0 mmol/L or an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (Table 1). Patients were randomized to eplerenone or placebo, and the eplerenone dose was based on renal function. Patients with eGFR ≥ 50 mL/min/1.73 m2 were started on 25 mg daily, which was increased to 50 mg daily after 4 weeks if serum potassium remained <5 mmol/L. Patients with eGFR 30–49 mL/min/1.73 m2 were started on 25 mg every other day, and the dose was increased to 25 mg once daily after 4 weeks if serum potassium remained <5 mmol/L. The primary endpoint of cardiovascular death or heart failure hospitalization was significantly lower in the eplerenone group (HR 0.63, 95% CI 0.54–0.74, P < 0.001). Importantly, eplerenone also significantly reduced the secondary endpoint of all-cause mortality (HR 0.76, 95% CI 0.62–0.93, P = 0.008).1 Serum potassium >5.5 mmol/L was observed in 11.8% of patients randomized to eplerenone and 7.2% of placebo patients (P < 0.001). The incidence of serum potassium >6 mmol/L was not different among eplerenone- and placebo-treated patients (2.5 vs. 1.9%, P = 0.29). Hypokalaemia (<3.5 mmol/L) was reported less often among eplerenone-treated patients (7.5 vs. 11%, P = 0.002).1 Study drug was discontinued due to an adverse event in 13.8% of eplerenone patients and 16.2% of placebo patients (P = 0.09). EMPHASIS-HF reflected contemporary use of evidence-based therapies, with 94% of patients receiving an ACE-inhibitor, ARB, or both, and 87% of patients receiving a beta-blocker (Table 2).

View this table:
Table 2

Comparison of study populations

Trial/drugNNYHA class II/III/IV (%)Mean LVEFIschaemic Aetiology (%)Background therapy (%)Placebo Mortality (1-year) (%)NNT (to save 1 life in 1 year)
ACEI or ARBBeta-blockerCRTICD
RALES2 and spironolactone16630.5/72/2725.6 ± 6.7559511n/an/a27.39
EPHESUS3 and eplerenone664290% with HF symptoms33 ± 61008675n/an/a13.650
EMPHASIS-HF1 and eplerenone2737100/0/026.2 ± 4.669.79486.62.8137.151
Figure 3

Kaplan–Meier estimates of cardiovascular death or heart failure hospitalization in EMPHASIS-HF. From New England Journal of Medicine, Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms, Volume 364, page 16. Copyright © (2011) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Current indications

The evidence supports the conclusion that an MRA improves survival in patients with HF–REF and mild-to-severe symptoms, and in patients with left ventricular systolic dysfunction and heart failure after AMI. The consistent findings in all three landmark trials of a significant benefit on all-cause mortality and on cardiovascular hospitalization in the overall study populations and across a variety of subgroups provide a robust level of evidence similar to that supporting ACE-inhibitor and beta-blocker use in HF–REF. An MRA is recommended by major professional society guidelines for patients with chronic heart failure and left ventricular systolic dysfunction and heart failure after AMI (Table 3).812 Although adverse renal and potassium effects occur with these agents, they can be managed with appropriate patient selection, close monitoring, and regular follow-up as addressed later in this manuscript.

View this table:
Table 3

Guideline recommendations for mineralocorticoid receptor antagonist

ESC11HFSA9,12ACC/AHA8Canadian10
Chronic HF
  • An MRA is recommended for all patients with persisting symptoms (NYHA class II–IV) and an EF ≤35%, despite treatment with an ACE-inhibitor (or an ARB if an ACE-inhibitor is not tolerated) and a beta-blocker, to reduce the risk of HF hospitalization and the risk of premature death

  • Class I, level of evidence A

  • Is recommended for patients with NYHA class II*-IV HF from reduced LVEF (<35%) while receiving standard therapy, including ACE-inhibitor (or ARB if ACE-inhibitor is not tolerated) and beta-blocker. Strength of evidence A

  • *For NYHA class II, high-risk modifiers should also be present: LVEF ≤30% (if LVEF 30–35, then QRS > 130 ms should also be present), age >55 years, HF hospitalization within 6 months [if no hospitalization within 6 months then BNP > 250 pg/mL or NT-proBNP > 500 pg/mL (men) or 750 pg/mL (women) should be present].

Is recommended in selected patients with moderately severe-to-severe symptoms of heart failure and reduced LVEF who can be carefully monitored for preserved renal function and normal potassium concentration. Class I recommendation, level of evidence BAn aldosterone receptor blocking agent such as eplerenone should be considered for patients with mild-to-moderate (NYHA II) HF, aged >55 years with LV systolic dysfunction (LVEF ≤30%, or if LVEF > 30% and ≤35% with QRS duration >130 ms), and recent hospitalization for CVD or elevated BNP/NT-pro-BNP levels who are on standard HF therapy. Strong recommendation, high-quality evidence
Post-MI LVDNo separate recommendation, included in chronic HF recommendationShould be considered in patients following an acute MI with clinical HF signs and symptoms or history of diabetes mellitus, and an LVEF <40%. Patients should be on standard therapy, including an ACE-inhibitor (or ARB) and a beta-blocker. Strength of evidence AIs recommended in carefully selected patients with LV dysfunction early after MI

Potential mechanisms of benefit for mineralocorticoid receptor antagonists

Fibrosis and remodelling

Aldosterone has long been recognized as an important contributor to heart failure pathophysiology (Figure 4).1316 It stimulates the reabsorption of sodium and the excretion of potassium in the renal distal tubule. Aldosterone stimulates cardiac fibrosis, and this mechanism is one of the particular interest with regard to heart failure progression, although it is unlikely to be the only important mechanism.1721 Several studies in animal models have shown increases in myocardial collagen and fibrosis in the presence of aldosterone.17,18,2224 Treatment with spironolactone blocked the aldosterone-mediated increase in collagen synthesis17,22 and other measures of remodelling25 in the rat. Dogs with systolic dysfunction produced by serial coronary microembolization randomized to receive eplerenone had a significantly higher LVEF and significantly lower LV volumes and end-diastolic pressure after 3 months when compared with controls.26 These experimental observations may provide insight into the underlying mechanism of benefit for MRAs in humans, and they provide the basis for testing the hypothesis that MRAs may reduce remodelling. Remodelling is a known predictor of poor outcome, and it is a major determinant of heart failure progression.27

Figure 4

The renin–angiotensin–aldosterone system and mineralocorticoid receptor antagonist mechanism of action.

In a substudy of the RALES trial, blood samples at baseline and 6 months were collected in 151 patients for analysis of markers of extracellular matrix (ECM) turnover [procollagen type III aminoterminal peptide (PIIINP), procollagen type I carboxy-terminal peptide (PICP), procollagen type I amino-terminal peptide (PINP), matrix metalloproteinase 1 (MMP1), tissue inhibitor of metalloproteinase 1 (TIMP1), and the MMP1/TIMP1 ratio].28 Compared with baseline, PINP and PIIINP levels were significantly lower at 6 months in patients randomized to spironolactone but not placebo. A hypothesis-generating subgroup analysis based on a small number of patients and events suggested that the effect of spironolactone on all-cause mortality was most apparent among patients with ECM turnover markers above the median value.28 Further research is needed to determine the clinical relevance of these preliminary findings.

Prospective, randomized trials in humans evaluating the effect of MRA therapy on remodelling markers have shown inconsistent results. In a randomized study of canrenoate, an intravenous MRA, followed by spironolactone for 1 month in 134 patients with acute MI, patients treated with the MRA had significantly less absolute change in LVEF and LV volumes when compared with non-MRA-treated patients.29 The absolute change in ECM turnover (e.g. PIIINP values) was also significantly less in the MRA group when compared with the non-MRA group, which correlated with the absolute change in LV volumes.29

However, a randomized, double-blind, placebo controlled study in 226 patients with LVEF ≤ 35% and NYHA class II-III heart failure found no difference in LVEDI or LVESI after 36 weeks of treatment with eplerenone 50 mg/day or placebo. The population was well treated at baseline with >95% on an ACE-inhibitor or ARB and 97% on a beta-blocker.30 The authors speculated that the lack of observed effect on remodelling may have been due to the short observation period in the setting of excellent background therapy. They also acknowledged that additional effects on remodelling may not be possible on top of optimal neurohormonal blockade. The authors reported an exploratory, hypothesis-generating finding of greater reductions in EDVI and ESVI in patients treated with eplerenone whose baseline PINP levels were greater than the median.30 This finding warrants further study.

In a substudy of EPHESUS involving 476 patients, the procollagen peptide PINP increased in all patients from baseline to month 1. By 6 months and persisting at 9 months, PINP and PIIINP levels were significantly lower among patients randomized to eplerenone with values approaching those at baseline. No between-group differences in TIMP-1 or type I collagen telopeptide (ICTP) were observed.31

A post hoc analysis of the EPHESUS data suggests that eplerenone produced a mild short-term diuretic effect associated with a potassium-sparing effect, which were both independently associated with better outcomes.32 However, eplerenone's beneficial effects on long-term survival and cardiovascular outcomes were independent from the early potassium-sparing or diuretic effects, suggesting that MRAs provide cardiovascular protection beyond the diuretic and potassium-sparing properties.32

The clinical relevance of the potential effect of MRAs on remodelling in humans has not been conclusively demonstrated. More research is needed to determine the clinical application of these findings. Several hypotheses have been developed around the concept of MRAs and remodelling. It is possible that in the future, fibrosis markers can be used to identify high-risk patients that would particularly benefit from MRA therapy. It is also plausible that early MRA treatment may limit the development of cardiac fibrosis, which could have a major impact on heart failure development and disease progression. These and other hypotheses, such as the role of MRAs in the treatment of heart failure with preserved ejection fraction, are currently being studied.33

Most important is the fact that both spironolactone and eplerenone have improved survival and reduced morbidity in large, prospective, randomized trials. Seeking to understand the potential mechanisms underlying observed clinical benefits can be useful to develop hypotheses for further study.

Arrhythmia

Myocardial fibrosis has been linked to arrhythmogenesis.3436 Sudden cardiac death is a common mode of death among patients with heart failure, and it accounts for the greatest proportion of deaths in patients with mild symptoms. Atrial fibrillation is also common in the heart failure population.37,38

Animal studies have shown reductions in interstitial fibrosis, atrial fibrosis, and inducible arrhythmias for both spironolactone and eplerenone.39,40 In a transgenic mouse model with conditional cardiac-specific overexpression of the human mineralocorticoid receptor (MR), mice exhibited a high rate of death that was prevented by spironolactone. Cardiac MR overexpression led to ion channel remodelling, resulting in prolonged ventricular repolarization at both the cellular and integrated levels and in severe ventricular arrhythmias.41

In the RALES trial, spironolactone reduced sudden death [10 vs. 13.1%, RR 0.71 (95% CI 0.54–0.95), P = 0.02] as well as heart failure death [15.5 vs. 22.5%, RR 0.64 (95% CI 0.51–0.80), P < 0.001].2 In EPHESUS, eplerenone significantly reduced sudden death [4.9 vs. 6.1%, RR 0.79 (95% CI 0.64–0.97), P = 0.03].3 Deaths due to acute MI and heart failure were numerically lower in the eplerenone group and the point estimate for risk reduction favoured eplerenone, but the difference did not reach statistical significance.3 Eplerenone was also associated with significant reductions in sudden death and total mortality in the early post-MI period (first 30 days), when patients are at the greatest risk of sudden death.42

In EMPHASIS-HF, the incidence of new onset atrial fibrillation or flutter was a pre-specified secondary endpoint. A subanalysis was performed that included 911 patients in the eplerenone group and 883 patients in the placebo group without a history of atrial fibrillation or flutter at baseline.43 The incidence of new onset atrial fibrillation was 2.7% in the eplerenone group and 4.5% in the placebo group (HR 0.58, 95% CI 0.35–0.96, P = 0.034). The reduction in new onset atrial fibrillation or flutter observed with eplerenone occurred in patients already treated with a RAAS inhibitor (94% on ACE-inhibitor or ARB in the overall EMPHASIS-HF population). Previous retrospective studies and meta-analyses have shown reductions in new onset atrial fibrillation with other RAAS inhibitors,4447 although treatment with valsartan did not reduce recurrent atrial fibrillation in a prospective study in patients without heart failure.48 Although MRAs may reduce arrhythmogenic potential by a number of different possible mechanisms, the exact mechanism is unknown.49 It should be acknowledged that any therapy that reduces left atrial size or stretch has the potential to influence the occurrence of atrial fibrillation. Thus, this observation may not be specific to MRAs.

Class or drug-specific effect?

The MRA drug class is comprised of three agents: spironolactone, eplerenone, and canrenoate. Spironolactone and eplerenone are oral agents and have been widely studied in large randomized controlled trials.13 Potassium canrenoate is available in both intravenous and oral formulations in some countries. It has been evaluated for its anti-remodelling effects both in mild heart failure50 and after AMI.51,52 It has not been studied in a prospective, randomized, adequately powered clinical outcome trial, and therefore is used to a lesser extent than spironolactone or eplerenone. Thus, the remainder of this discussion will focus on spironolactone and eplerenone.

Comparative studies

Both spironolactone and eplerenone improve survival and reduce morbidity, but they have been studied in different populations (Table 2). Hypertension studies have evaluated spironolactone and eplerenone, but direct comparisons of the agents were not performed.53,54 Head to head comparison trials of these agents in heart failure patients are also lacking.

In vitro competition binding assays in the rat model have shown that eplerenone binds to the MR with an approximately 20-fold lower affinity than spironolactone.55,56 However, the eplerenone dose required to inhibit aldosterone binding in vivo was half of that required for spironolactone, suggesting that eplerenone is more potent, even though it binds to the MR with a lower affinity. In the context of its binding properties and its potency, an approximate two-fold higher dose of eplerenone is needed to exert the same pharmacologic effects as spironolactone. This factor should be considered when evaluating any comparative data between eplerenone and spironolactone.

HbA1c and serum cortisol

Eplerenone and spironolactone may have differential effects on biomarkers, but the observed differences are not definitive and the clinical relevance of these effects is unknown. In a study of 107 stable outpatients with mild heart failure, patients randomized to spironolactone 25 mg daily experienced increases in HbA1c and serum cortisol levels. In contrast, patients randomized to eplerenone 50 mg daily demonstrated no change in these markers.57 Cortisol is an independent risk factor for mortality in patients with HF–REF.58 Cortisol also binds to and activates the MR, and there is some evidence that eplerenone blocks cortisol-induced MR activation.59 These results are consistent with previous studies demonstrating that spironolactone was associated with increases in cortisol and HbA1c.60,61 Although spironolactone has been shown to improve endothelial function in patients with heart failure,62,63 it may worsen endothelial function and heart rate variability, and increase HbA1c and angiotensin II levels in patients with type II diabetes (heart failure patients were excluded in this study).61 However, these effects may not influence clinically relevant outcomes. Data from randomized trials suggest that patients with diabetes benefit from either eplerenone or spironolactone to a similar degree as patients without diabetes. In a substudy of EPHESUS, the benefit of eplerenone on the primary endpoint of cardiovascular mortality or cardiovascular hospitalization was preserved in patients with diabetes [35.8% eplerenone vs. 40.9% placebo, RR 0.83 (0.71–0.98), P = 0.031] and no changes in glycaemic control were reported.64 Similar findings were reported in RALES, where the mortality benefit of spironolactone compared with placebo was similar in patients with diabetes (HR 0.70, 95% CI 0.52–0.94, P = 0.019) and in those without (HR 0.70, 95% CI 0.60–0.82, P = 0.001).

Pharmacologic differences

Pharmacologic differences exist between eplerenone and spironolactone (Table 4).6568 Both drugs improve clinical outcomes; thus, these pharmacologic differences are not related to outcomes, but they may be relevant to individual patients for tolerability or practical reasons. Spironolactone is a non-selective MRA. It also binds to progesterone and androgen receptors, leading to adverse effects such as gynecomastia and impotence in men and menstrual irregularities and breast tenderness in women. In the RALES trial, the incidence of gynecomastia or breast tenderness in men among patients randomized to spironolactone was 10%.2 Eplerenone is a selective inhibitor of the MR and is generally devoid of antiandrogenic side effects.67,68 The incidence of gynecomastia in men randomized to eplerenone was 0.5 and 0.7% in the EPHESUS and EMPHASIS-HF trials, respectively.1,3 Thus, eplerenone should be prescribed to patients who experience gynecomastia or breast tenderness on spironolactone. Rates of renal or potassium related adverse effects are generally similar between the drugs at equipotent doses. Spironolactone as the parent compound has a short half-life (1–2h), but its active metabolite canrenone has a half-life of up to 35 h. The half-life of eplerenone is much shorter (4–6 h), and it does not have active metabolites. The prolonged half-life of spironolactone may contribute to a slow reversal of hyperkalaemia after spironolactone is down-titrated or discontinued. This hypothesis is based on the known pharmacokinetics of the drug, yet clinical data are lacking.69

View this table:
Table 4

Mineralocorticoid receptor antagonist pharmacology6568

SpironolactoneEplerenone
Mineralocorticoid receptor selectivityNon-selectiveSelective
Absorption∼100% bioavailable (with food)69%
Distribution90% protein bound50% protein bound
MetabolismHepatic, active metabolites (canrenone)Hepatic cytochrome P450 3A4 (inactive metabolites)
Excretion
  • Primarily renal

  • Half-life (parent): 1–2 h

  • Half-life (metabolites): 10–35 h

  • Primarily renal

  • Half-life: 4–6 h

Drug interactionsPharmacodynamic interactions with other drugs that also raise potassium: potassium-sparing diuretics, potassium salts or supplements, NSAIDs, pentamidine, drospirenone, trimethoprim, heparin, IV penicillin G potassium, potassium iodide, tolvaptan, cyclosporine, tacrolimus
  • CYP 3A4 substrate

  • Eplerenone plasma levels will increase in the setting of strong CYP 3A4 inhibitors (i.e. ketoconazole, erythromycin, clarithromycin, see Table 5)

  • Pharmacodynamic interactions with drugs that raise serum potassium, as listed for spironolactone

The drug interaction profile also differs between the two agents. Eplerenone is metabolized by the cytochrome P-450 3A4 isoenzyme, and eplerenone serum concentrations may increase in the presence of other drugs that inhibit CYP 3A4. This interaction is of particular clinical relevance because it may increase the risk of hyperkalaemia, which is a dose-dependent side effect. Select drugs that inhibit CYP 3A4 are shown in Table 5. Co-administration of these drugs with eplerenone should be avoided when possible. If concomitant administration is required, the eplerenone dose may need to be reduced or therapy temporarily interrupted to reduce the risk for hyperkalaemia. Additional monitoring of serum potassium should be implemented. If long-term therapy with an interacting drug is clinically necessary, then prescribing spironolactone may be preferred, since it is not a CYP 3A4 substrate. It should be noted that many compounds inhibit CYP 3A4 but have not been investigated for their effects on eplerenone serum concentrations. A prudent clinical course of action is to monitor serum potassium more closely any time a CYP 3A4 inhibitor is used in conjunction with eplerenone, regardless of whether or not an increase in eplerenone AUC has been reported. The onset of the interaction will depend on the pharmokinetic properties of the CYP 3A4 inhibitor.

View this table:
Table 5

Select inhibitors and inducers of the cytochrome P-450 3A4 isoenzyme66,103,104

Concomitant drugEstimated effect on eplerenone AUC66
Inhibitor
 Ketoconazole5.4-fold increase
 Erythromycin2–2.9-fold increase
 Verapamil
 Saquinavir
 Fluconazole
 Grapefruit juice25% increase
 CisaprideNo clinically significant effect
 Cyclosporine
 Digoxin
 Glyburide
 Midazolam
 Norethindrone/ethinyl estradiol
 Simvastatin
 Warfarin
 IndinavirNo data documenting influence of interaction on eplerenone AUC. The potential exists for eplerenone AUC to be increased with concomitant use of these drugs, but the extent and clinical significance of the interaction has not been quantified. Additional monitoring and/or decreased eplerenone dose may be warranted
 Nelfinavir
 Ritonavir
 Clarithromycin
 Itraconazole
 Nefazodone
 Telithromycin
 Diltiazem
 Cimetidine
 Amiodarone
 Chloramphenicol
 Ciprofloxacin
 Delavirdine
 Fluvoxamine
 Imatinib
 Fluoxetine/norfluoxetine
 Voriconazole
 Conivaptan
 Zafirlukast
 Efavirenz
 Ranolazine
 Nilotinib
Inducers
 St John's Wort30% decrease
 NevirapineNo data documenting influence of interaction on eplerenone AUC. The potential exists for eplerenone AUC to be reduced with concomitant administration of these drugs, but the extent and clinical significance of the interaction has not been quantified. Additional monitoring may be warranted
 Barbiturates
 Carbamazepine
 Oxcarbazepine
 Glucocorticoids
 Modafinil
 Phenytoin
 Pioglitazone
 Rifampin

Other considerations for drug selection

Robust scientific evidence demonstrating improved survival and reduced morbidity exists for both spironolactone and eplerenone. For spironolactone, the evidence is limited to patients with severe heart failure. For eplerenone, the evidence spans patients with mild heart failure symptoms to patients with left ventricular systolic dysfunction and symptomatic heart failure after AMI, but it does not currently include patients as severe as those enrolled in RALES (Table 2). Tangible differences between spironolactone and eplerenone exist: steroid hormone related adverse effects, half-life, drug interactions, and cost. Recognition of these differences may be helpful in guiding drug selection for individual patients. In general, the practice of evidence-based medicine requires that the drugs be used according to how they were studied in clinical trials; e.g. eplerenone in patients with mild heart failure symptoms or acute MI patients and spironolactone in patients with severe symptoms. However, intolerable side effects are appropriate reasons to use eplerenone instead of spironolactone in a patient with severe heart failure. Similarly, an inability to afford the medication or the presence of clinically significant drug interactions is an appropriate reason to use spironolactone in a patient with mild heart failure symptoms. Clinicians must use their knowledge of the evidence and the drug-specific differences to appropriately select the optimal regimen for their patients with heart failure.

Promoting patient safety

Dose response and the balance between efficacy and safety

The dosing strategies used in the major MRA clinical trials are shown in Table 6. Dose-related increases in serum potassium and upstream activation of the RAAS (as measured by increases in serum aldosterone and plasma renin) have been observed with MRAs in both hypertensive and heart failure patient populations.7,54,70,71

View this table:
Table 6

Dosing strategies used in the mineralocorticoid receptor antagonist randomized controlled clinical trials

TrialInitial dose (per day)Titration scheduleMean dose achieved (per day)Change in serum potassiumChange in serum creatinineIncidence of hyperkalaemia
RALES2 and spironolactone25 mg
  • Increased to 50 mg/day after 8 weeks

  • Dose could be reduced to 25 mg every other day for hyperkalaemia

26 mg0.3 mmol/L (median) during first year of follow-up0.05 to 0.1 mg/dL (median) during first year of follow-upSerum potassium ≥6 mmol/L: 2%
EPHESUS3 and eplerenone25 mg
  • Increased to 50 mg/day after 4 weeks

  • Dose reduced or temporarily discontinued for serum potassium >5.5 mmol/L

42.6 mg0.3 mmol/L at 1 year0.06 mg/dL at 1 yearSerum potassium ≥6 mmol/L 5.5%
EMPHASIS-HF1 and eplerenone25 mg (eGFR ≥50 mL/min/1.73 m2) or 25 mg every other day (eGFR 30–49 mL/min/1.73 m2)
  • Increased to 50 mg/day after 4 weeks

  • For eGFR 30–49 mL/min/1.73 m2: increased to 25 mg/day

  • Decrease dose for serum potassium 5.5–5.9 mmol/L

  • Withhold drug for serum potassium ≥6 mmol/L

  • 39.1 ± 13.8 mg

  • 60.2% of patients were receiving 50 mg/day at completion of the 5-month dose adjustment phase)

0.16 ± 0.56 mmol/L at trial cut-off date0.09 ± 0.37 mg/dL at the trial cut-off date
  • Serum potassium >5.5 mmol/L: 11.8%

  • >6 mmol/L: 2.5%

Hyperkalaemia

The rate of hyperkalaemia in the major MRA clinical trials ranges from 2 to 11.8%, depending on the definition. It is important to note that no deaths attributable to hyperkalaemia were reported in RALES, EPHESUS, or EMPHASIS-HF. Several studies have suggested that the rate of hyperkalaemia is higher in general practice where rigorous monitoring protocols required by clinical trials are not consistently in place. In an analysis from Ontario, an increase in hospitalization for hyperkalaemia and hyperkalaemia-related mortality was observed after publication of the RALES data.72 This finding was not replicated in a longitudinal analysis of the UK National Health Service in Scotland.73 In this study, an increase in mild hyperkalaemia was reported after the publication of RALES, but it did not translate into increased hospitalizations or death due to hyperkalaemia.73 The authors attributed the finding to more rigorous monitoring practices. Other studies have also reported higher rates of hyperkalaemia and increases in serum creatinine in clinical practice than observed in randomized controlled trials.74 However, studies performed in heart failure clinics appear to have rates of hyperkalaemia (4–6%) that are within the range of those observed in clinical trials.75 In the EPHESUS study, changes in serum potassium did not influence the effect of eplerenone on all-cause mortality. The benefit of eplerenone on total mortality was present regardless of potassium change.76

Although hyperkalaemia is generally the aspect of potassium homeostasis that is discussed in the context of MRAs, hypokalaemia is also clinically important. Some data suggest that hypokalaemia in patients with heart failure may be associated with increased mortality, even among patients with chronic kidney disease.7779 In the AMI population, a U-shaped curve was identified with respect to post-admission serum potassium and in-hospital mortality. In this analysis, serum potassium levels <3.5 as well as >4.5 mEq/L were associated with higher mortality.80 In EPHESUS, the rate of serious hypokalaemia (serum potassium <3.5 mmol/L) was 8.4% in the eplerenone group and 13.1% in the placebo group (P < 0.001). In EMPHASIS-HF, serum potassium <3.5 mmol/L was reported in 7.5% of the eplerenone group and 11% in the placebo group (P = 0.002). Prospective studies are needed to evaluate whether prevention of hypokalaemia by an MRA or other agents alters clinical outcomes.

Renal impairment

The change in serum creatinine observed with a MRA in the highly selected patients enrolled in clinical trials is relatively small (Table 6). In a systematic review, worsening renal function was reported in 8.9% of patients randomized to an MRA compared with 1.6% of control patients.81 However, definitions of worsening renal function differed across trials (e.g. 25% increase in eGFR or serum creatinine increases of >0.3 mg/dL), making these data difficult to interpret. In an analysis of EPHESUS, eplerenone was associated with a lower eGFR within the first month of treatment (adjusted difference, −1.3 ± 0.4 mL/min/1.73 m2) relative to placebo.82 In multivariate analyses, in addition to eplerenone treatment, other factors that independently predicted early worsening renal function (defined as a decrease in eGFR >20% at 1 month) included female sex, age ≥65 years, LVEF <35%, smoking, and baseline use of loop diuretics or antiarrhythmics. Baseline potassium (per 0.5 mmol/L increment), baseline eGFR <60 mL/min/1.73 m2, baseline use of statins, and mean blood pressure change at 1 month (per 10 mmHg increment) were associated with a lower risk of early worsening renal function. The benefit of eplerenone on clinical outcomes persisted despite the early worsening of renal function in some patients.82

Data from non-heart failure patients may lessen concerns related to MRA renal adverse events. Aldosterone has been implicated in the development and progression of renal disease in hypertension and in patients with diabetes.83,84 Both eplerenone and spironolactone reduce albuminuria in patients with type 2 diabetes mellitus and chronic kidney disease.85 It should be acknowledged that albuminuria is a surrogate marker, and whether this finding translates into improved outcomes in this population remains to be determined. One could speculate that the combination of an increase in serum creatinine and a reduction in microalbuminuria suggests that MRAs reduce intraglomerular pressure, thereby protecting the kidney in the long term. A meta-analysis of 11 randomized, controlled trials of an MRA in patients with chronic kidney disease, albuminuria, or proteinuria due to both diabetic and non-diabetic nephropathy demonstrated that the MRA was associated with significant reductions in proteinuria without changes in renal function.86 Thus, it is possible that, as with ACE-inhibitors, MRAs are associated with short-term harm to the kidneys but provide benefits over the medium to long term.82 Moreover, studies in diabetic nephropathy demonstrate that the greater the initial decrease of kidney function with RAAS blockade, the greater the long-term preservation of kidney function.87 This hypothesis requires further study using robust clinical endpoints. It is also important to emphasize that hyperkalaemia and worsening renal function are among the main adverse events of other RAAS inhibitors, especially when two are used in combination. These adverse effects appear to be inherent to the pharmacological effect of RAAS blockade.88,89

Predicting, preventing, and managing renal and potassium safety issues

In a post hoc analysis of EPHESUS, independent predictors of serum potassium ≥6 mEq/L were eGFR <60 mL/min/1.73 m2, history of diabetes mellitus, baseline serum potassium >4.3 mEq/L, and prior antiarrhythmic use. Statistically significant between-group differences in the proportion of patients with hyperkalaemia were only observed in the subgroup of patients with baseline eGFR < 60 mL/min/1.73 m2.76 One small study identified that the presence of the 215G allele in the gene for the NR3C2 (or mineralocorticoid) receptor was associated with a higher risk for potassium increases >0.5 mEq/L after initiation of spironolactone.90

Strict adherence to the dosing and monitoring regimens used in clinical trials should be used in clinical practice (Table 7). In a retrospective cohort study among patients managed by health maintenance organizations, appropriate potassium and serum creatinine monitoring were not performed in 28% of patients.91

View this table:
Table 7

Suggested dosing and monitoring strategies for mineralocorticoid receptor antagonist in heart failure

Recommended doseRenal and potassium contraindicationsMonitoring time pointsaDose adjustment
  • Spironolactone 25 mg once daily, titrated to 50 mg once daily

  • Eplerenone 25 mg once daily (or 25 mg every other day for eGFR 30–49 mL/min/1.73 m2), titrated to 50 mg once daily (or 25 mg once daily for eGFR 30–49 mL/min/1.73 m2)

Serum potassium >5 mmol/L or eGFR < 30 mL/min/1.73 m2
  • Within 72 h after initiation

  • At 4 weeks

  • Every 3–4 months routinely

  • Within 72 h after any dose adjustment or other change in clinical or drug status that might influence the risk of hyperkalaemia or renal impairment

  • Decrease dose for serum potassium >5.5 mmol/L

  • Hold dose for serum potassium >6.0 mmol/L

  • Restart therapy or increase back to previous dose when serum potassium <5.0 mmol/L

  • aSlight variations of monitoring time points were used across clinical trials. These suggested monitoring time points are based on those most commonly used in the clinical trials. More frequent monitoring may be clinically indicated in some patients. Clinical judgment is recommended.

The risk of hyperkalaemia can be further reduced by ensuring dietary and other pharmacologic sources of potassium are minimized. Salt substitutes are common sources of dietary potassium in patients with heart failure. Patients receiving MRAs should be educated to avoid salt substitutes and encouraged to season foods with non-sodium- and non-potassium-based spices. Select high potassium containing foods are shown in Table 8. A comprehensive listing of the potassium content of many common foods can be found at http://www.ars.usda.gov/ba/bhnrc/ndl. Nutritional supplement drinks are also generally high in potassium, and should be used cautiously in combination with an MRA. However, it is unknown to what extent dietary potassium intake should be limited in patients treated with an MRA, and further research is needed to clarify this issue.

View this table:
Table 8

Select dietary sources of potassium

SourceWeight (g)Common measureaPotassium content per measure (mg)
Tomato paste, canned2621 cup2657
Orange juice, frozen concentrate2136 fl. oz. can1436
Beet greens, boiled1441 cup1309
White beans, canned2621 cup1189
Dates, deglet noor1781 cup1168
Milk, canned, condensed3061 cup1135
Tomato puree, canned2501 cup1098
Raisins1451 cup1086
Potato, baked2021 potato1081
Grapefruit juice, white, frozen concentrate2076 fl. oz. can1002
Soybeans, cooked1801 cup970
Lima beans, boiled1881 cup955
Plantains, raw1791 medium893
Refried beans, canned2521 cup847
Halibut159½ fillet840
Spinach, cooked1801 cup839
Tomato sauce2451 cup811
Prunes2401 cup796
Sweet potato, canned2551 cup796
Beans, pinto1711 cup746
Carrot juice, canned2361 cup689
Salmon155½ fillet632
Black beans1721 cup611
Yogurt2278 oz579
Mushrooms1561 cup555
Bananas1501 cup537
Broccoli1561 cup457
Brussels sprouts1551 cup450
Cucumber, with peel3011 large442
Cantaloupe1601 cup427
Turkey, roasted1401 cup417
Strawberries, raw1661 cup254
Carbonated beverage, cola12 fl oz7
LicoriceCan be a cause of hypokalaemia
  • Adapted from US Department of Agriculture, Agricultural Research Service. 2011. USDA National Nutrient Database for Standard Reference, Release 24. Nutrient Data Laboratory Home Page, http://www.ars.usda.gov/ba/bhnrc/ndl.a1 cup ∼8 oz ∼240 mL.

In addition to foods, other drugs can raise serum potassium levels and should be avoided whenever possible. These include, but are not limited to potassium-sparing diuretics, potassium salts or supplements, non-steroidal anti-inflammatory drugs (NSAIDs), pentamidine, drospirenone, trimethoprim,92 heparin, penicillin G potassium (IV), potassium iodide, tolvaptan, cyclosporine, and tacrolimus. Current guidelines recommend avoiding triple therapy with an ACE-inhibitor, ARB, and an MRA because of the unclear clinical benefit and the incremental risk of hyperkalaemia.8,9,93 A post hoc analysis of the CHARM-added study showed that the reduction in cardiovascular death or heart failure hospitalization among the subgroup of patients receiving spironolactone at baseline was similar to that observed in the overall population. The proportion of patients who discontinued study drug (candesartan) because of increased serum creatinine or hyperkalaemia appeared to be the greatest in the subgroup of patients also treated with spironolactone.94

Achieving evidence-based clinical practice: are we there yet?

Strong recommendations from international guidelines support the use of MRAs in heart failure patients with reduced ejection fraction similar to those studied in the large randomized MRA trials.810,93,95 It has been projected from national statistics and registry data in the USA that 603 014 patients with heart failure are eligible for treatment with an MRA, but only 36.1% receive the therapy.96 It was further estimated that an additional 21 407 lives could be saved each year in the USA, if an MRA was used in appropriate patients.96 These figures were based on existing indications for MRA prior to the publication of EMPHASIS-HF, and therefore underestimate the number of patients with mild heart failure symptoms who will also likely be considered eligible in future guidelines.

In an analysis of data from the Get With the Guidelines Heart Failure quality improvement registry, only 32.5% of 12 565 eligible patients were prescribed an MRA at the time of discharge from a heart failure hospitalization.97 These data were collected from January 2005 through December 2007, 6–8 years after the publication of RALES. The widespread adoption of this therapy continues to lag significantly behind the evidence.

An MRA was prescribed to 43.7% of 3226 outpatients enrolled in the EURObservational Research Programme Heart Failure Pilot Survey, conducted from October 2009 to May 2010; however, a large proportion of patients in the survey had LVEF >30%.98 Among patients hospitalized for heart failure in this survey, approximately 35% were receiving an MRA on admission. This proportion increased to approximately 55% during the hospitalization.98 In the IMPROVE-HF registry (Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting) conducted in outpatient cardiology practices, the use of an MRA in patients with an appropriate indication was 34.5% at baseline and had improved to 60.3% at 24 months.99 Focused process of care initiatives and clinician education can be effective measures to improve the use of MRAs in appropriate patients.

Conclusion

Mineralocorticoid receptor antagonists confer important clinical benefits to heart failure patients with mild-to-severe symptoms. They reduce total mortality and hospitalizations on top of ACE-inhibitors and beta-blockers.100 Several possible mechanisms have been postulated to explain the observed clinical benefits. Antifibrotic and reverse remodelling effects are of particular interest, but remodelling studies in humans have been inconclusive. The exact mechanism of benefit has yet to be determined. Other methods of interfering with the deleterious effects of aldosterone, such as aldosterone synthase inhibition which decreases the production of aldosterone, are also under development.101,102 However, the regulation of aldosterone is complex, and because MRAs and aldosterone synthase inhibitors address different pathways (receptor blockade vs. ligand production), these drug classes will not be interchangeable. Whether aldosterone synthase inhibitors will be a safe and effective treatment modality for patients with heart failure remains to be determined in clinical trials.

Importantly, both eplerenone and spironolactone improve survival and reduce hospitalizations. Pharmacologic differences between the agents may be useful to inform drug selection for individual patients. Mineralocorticoid receptor antagonists are being evaluated in several new patient populations, including heart failure with preserved systolic function,33 ST segment elevation MI without heart failure, end stage renal disease on haemodialysis, atrial fibrillation, diabetic nephropathy, and other diseases where aldosterone contributes to disease pathology. As the totality of evidence grows, new strategies are needed to ensure the uptake of clinical trial evidence into clinical practice, from appropriate patient selection to optimal monitoring practices. The expansion of guideline recommendations for MRAs to include less sick patients may serve as a stimulus to develop such strategies or processes of care. These steps will lead to improved outcomes for patients with heart failure, left ventricular systolic dysfunction, and heart failure after AMI, and potentially additional diseases in the future.

Funding

This work was generated from discussions during the Eighth Global Cardiovascular Clinical Trialists (CVCT) Forum held in Paris, France, in December 2011. CVCT was organized by the Clinical Investigation Center (CIC) Inserm, CHU, and University Henri Poincaré of Nancy, France and funded by an unrestricted educational grant from Association de Recherche et d'Information en Cardiologie (ARISC) a non-profit educational organisation, in Nancy, France. ARISC had no involvement in preparation, review, or approval of the manuscript for publication.

Conflict of interest: F.Z.: Pfizer, Inc. (steering committee). W.G.S.: INSERM, Centre d'Investigation Clinique, Centre Hospitalier Universitaire, Nancy, France (travel expense reimbursement to attend CVCT 2011 and professional time related to preparation of this paper). P.R.: Travel grants from Pfizer (modest). J.B.: Research support and honoraria for lectures from Pfizer regarding eplerenone. J.J.V.M.: Support paid to Glasgow University for time serving as Executive Committee member for EMPHASIS-HF; honoraria from Pfizer for serving as chair/speaker at Pfizer sponsored symposia at cardiology congresses. A.D.S.: Consultant to three companies developing MRAs, including Pfizer (names of other companies are confidential). L.M.R.: Speaker/advisor for Actelion-Merck, Bayer, BMS, Boehringer-Ingelheim, Daiichi-Sankyo, Medtronic, Novartis, Otsuka, Pfizer, Roche, Servier, Takeda. G.L.B.: Investigator Initiated Grant/Research Support-(direct funding to University of Chicago): Forest Labs; National Clinical Trial Principal Investigator Studies: Medtronic, Relapysa; Consultant: Takeda, Abbott, CVRx, Johnson & Johnson, Eli Lilly, Food and Drug Administration; Speaker Bureaus: Takeda; Boards: National Kidney Foundation, American Society of Hypertension; Journals: Editor, American Journal of Nephrology; Associated Editor, Diabetes Care, Nephrology Dialysis and Transplantation. A.C.-S.: Research grants from Amgen, Novartis, Bayer; Consultant to Genzyme, VIFOR, GE Healthcare, IPSEN, Thermofisher, Abbott, Bayer; Speaker for Servier. F.B.: Lecture fees from Roche, Servier, Sanofi-Aventis, Pfizer, and Astellas; Research grants from Pfizer, BRAHMS, Federation Francaise de Cardiologie. G.S.F.: DSMB member in the eplerenone REMINDER trial, Steering Committee member ARTS MRA trial. Z.A.M.: Research grants and honoraria: FMC. A.P.: Consultant: Abbott, Pierre Fabre, MSD, Astra Zeneca; Boards: French Society of Hypertension; Journals: Editor, Fundamental and Clinical Pharmacology. I.L.P.: Consultant to the U.S. Food and Drug Administration. H.N.S.: Research grants: Bayer Healthcare AG; Bayer Healthcare AG. L.T.: Data Safety Monitoring Committee member for the EMPHASIS-HF trial, sponsored by Pfizer. B.P.: Consultant: Pfizer, Merck, Novartis, Bayer, Takeda, AstraZeneca, Relypsa, BG-Medicine, Aurasence, Cytopherx, Amorcyte, GE-health care; Grants: Novartis, Forrest Laboratories, Medtronic; Stock Options: Relypsa, BG-Medicine, Aurasence. Others none declared.

Acknowledgements

The following individuals were speakers or panelists discussing the topic of this manuscript at the December 2011 8th Global Cardiovascular Clinical Trialists Forum, Paris, France: Hans-Juergen Arens, Angeles Alonso, Michael Bristow, Michael Felker, Richard Isnard, Michael Mendelsohn, Frank Misselwitz, and Marc Pfeffer.

References

View Abstract